Epigenetic and Spatial Single-cell profiling in the context of Cancer Immunotherapy KU Leuven
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. One of the major limitations of ICB, however, is that it provides durable clinical responses only in a small fraction of patients. Moreover, to date, there is no reliable method to predict which patients will respond to ICB. Finally, many combined ICB therapies are currently being tested in numerous clinical ...